Atorvastatin for stroke prevention.
D000069059:Atorvastatin; D020202:Cerebral Hemorrhage, Traumatic / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005464:Fluorobenzenes / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D002546:Ischemic Attack, Transient / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D009135:Muscular Diseases / Q000139:chemically induced; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D012206:Rhabdomyolysis / Q000139:chemically induced; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D020521:Stroke / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin